Clinical Trial

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Name: BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease — clinical trial record (NCT04271644)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.

Protocol Amendment History 3 amendments

This ClinicalTrials.gov record has been amended 3 times since 2020-02-14; most recent amendment 2025-02-23.

Trial Details

NCT Number	NCT04271644
Lead Sponsor	Chongqing Precision Biotech Co., Ltd
Conditions	Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
Enrollment	80 participants
Start Date	2019-04-01
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-07-01 (estimated)
Updated on ClinicalTrials.gov	2025-02-25